

2024

Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth Oregon Region

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM NEGATIVE ORGANISM	PERCENT SUSCEPTIBLE	# Isolates Tested	Beta-lactams												Fluoro-quinolones	Aminoglycosides	Miscellaneous	
			Penicillins			Cephems				Carbapenems								
			Ampicillin	Amoxicillin/clavulanic acid	Piperacillin/tazobactam	Cefazolin	Ceftazidime	Ceftriaxone	Cefepime	Cefotaxime	Cefpodoxime	Ertapenem	Meropenem	Ciprofloxacin	Levofloxacin	Amikacin	Gentamicin	Tobramycin
<i>Citrobacter freundii</i> complex	79	R R 76*	R	73*	72*	100	R	67	100	100	90	84	100	98	97	81 (n=42)	86	91
<i>Citrobacter koseri</i>	36	R 97 100	-	-	100	100	97	-	100	100	100	100	-	100	100	-	100	-
<i>Enterobacter cloacae</i> complex	191	R R 78*	R	83*	78*	97	R	69	95	100	97	95	100	98	97	57 (n=88)	93	92
<i>Escherichia coli</i>	1934	62 89 97	91	97	94	97	95	91	100	100	83	81	100	95	95	97 (n=1613)	84	82
<i>Klebsiella aerogenes</i>	54	R R 74*	R	77*	80*	100	R	-	100	100	98	96	100	100	100	18 (n=33)	96	98
<i>Klebsiella oxytoca</i>	121	R 91 90	-	100	92	99	98	93	100	100	96	98	100	96	96	91 (n=68)	91	90
<i>Klebsiella pneumoniae</i>	360	R 94 94	89	95	92	96	95	91	99	100	87	86	100	98	97	34 (n=261)	85	91
<i>Morganella morganii</i>	65	R R 100	R	87	84	98	50	-	100	100	78	78	100	88	94	R 47	81	
<i>Proteus mirabilis</i>	223	79 100 100	94	99	96	100	96	92	100	100	83	83	100	91	92	R R	84	
<i>Pseudomonas aeruginosa</i>	343	R R 92	-	95	R	97	-	-	R	98	88	78	98	-	99	-	R R	
<i>Serratia marcescens</i>	76	R R 91	R	100	95	100	R	-	100	100	93	93	100	100	89	R 36	100	
<i>Stenotrophomonas maltophilia</i>	46	R R R	-	-	R	-	-	-	-	R	-	98	R R R	-	R	100		

* Third generation cephalosporins and piperacillin/tazobactam are unreliable for systemic infections with AmpC producing organisms (E. cloacae, K. aerogenes, or C. freundii), regardless of susceptibility data, due to the development of induced resistance on treatment.

Haemophilus influenzae beta lactamase positive (all Oregon): 27.6% (n=116)

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th Edition, January 2014.

2024

Cumulative Antimicrobial Susceptibility Report



INPATIENT DATA

PeaceHealth Oregon Region

January 1 – December 31, 2024

Dash (-) = not tested, inappropriate, or < 30 strains tested. R = intrinsically resistant.

GRAM POSITIVE ORGANISM	# Isolates Tested	Beta lactams					Fluoro-quinolones	Amino-glycosides	Miscellaneous											
		Penicillins/Cephalosporins				Ceftriaxone			Ciprofloxacin	Levofloxacin	Gentamicin Synergy	Streptomycin Synergy	Clindamycin	Daptomycin	Erythromycin	Minocycline	Nitrofurantoin - urine only			
		Penicillin	Oxacillin	Ampicillin	Cefazolin	Ceftriaxone			Rifampin	Tetracycline	Trimethoprim/sulfamethoxazole	Vancomycin								
<i>Enterococcus faecalis</i>	543	-	-	100	R	R	-	-	84	93	R	-	-	-	-	98 (n=315)	-	-	R	99
<i>Enterococcus faecium</i>	49	-	-	69	R	R	-	-	95	88	R	-	-	-	-	-	-	-	R	94
<i>Staphylococcus aureus</i> , MRSA	541	-	0	-	0	-	-	-	-	-	82	100	-	100	100 (n=30)	-	76	99	100	
<i>Staphylococcus aureus</i> , MSSA	1197	-	100	-	100	-	-	-	-	-	87	-	-	100	96 (n=52)	-	95	100	-	
<i>Staphylococcus epidermidis</i>	135	-	42	-	41	-	-	-	-	-	63	-	-	100	-	-	75	60	100	
<i>Staphylococcus lugdunensis</i>	93	-	95	-	95	-	-	-	-	-	85	-	-	100	-	-	98	100	100	
<i>Streptococcus agalactiae</i> (Group B)	98	100	-	-	100	100	-	-	-	-	48	-	40	-	-	-	-	-	100	
<i>Streptococcus anginosus</i>	132	100	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100	
<i>Streptococcus constellatus</i>	72	96	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100	
<i>Streptococcus intermedius</i>	48	100	-	-	-	100	-	-	-	-	-	-	-	-	-	-	-	-	100	
<i>Streptococcus mitis/oralis</i>	50	76	-	-	-	94	-	-	-	-	-	-	-	-	-	-	-	-	100	
<i>Streptococcus pneumoniae</i>	128	100*	-	-	-	100*	-	100	-	-	-	-	68	-	-	-	85	-	-	
<i>Streptococcus pyogenes</i> (Group A)	201	100	-	-	100	100	-	-	-	-	78	-	79	-	-	-	-	-	100	

*Non-meningitis breakpoint

Note: It is recommended that susceptibility data only be reported when there are at least 30 clinical isolates in the data set.

This antibiogram was created in compliance with CLSI M39-A4 Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline, 4th Edition, January 2014.